Free Trial
→ You missed yesterday's deadline… (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$461.26
-0.9%		$420.83
$294.48
▼
$475.64
$251.64B0.432.62 million shs2.36 million shs
Biogen Inc. stock logo
BIIB
Biogen
$248.93
0.0%		$228.34
$148.51
▼
$258.78
$36.81B0.11.35 million shs1.06 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$167.47
-1.7%		$151.77
$116.88
▼
$175.65
$211.27B0.356.41 million shs6.36 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,408.68
-0.2%		$1,204.03
$850.51
▼
$1,449.68
$1.33T0.42.62 million shs2.76 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-0.90%+2.97%+14.45%+13.10%+55.67%
Biogen Inc. stock logo
BIIB
Biogen
-0.03%-1.50%+13.21%+20.47%+64.38%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-1.68%+5.27%+15.70%+27.10%+37.21%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.24%+9.75%+23.11%+20.37%+57.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$461.26
-0.9%		$420.83
$294.48
▼
$475.64
$251.64B0.432.62 million shs2.36 million shs
Biogen Inc. stock logo
BIIB
Biogen
$248.93
0.0%		$228.34
$148.51
▼
$258.78
$36.81B0.11.35 million shs1.06 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$167.47
-1.7%		$151.77
$116.88
▼
$175.65
$211.27B0.356.41 million shs6.36 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,408.68
-0.2%		$1,204.03
$850.51
▼
$1,449.68
$1.33T0.42.62 million shs2.76 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-0.90%+2.97%+14.45%+13.10%+55.67%
Biogen Inc. stock logo
BIIB
Biogen
-0.03%-1.50%+13.21%+20.47%+64.38%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-1.68%+5.27%+15.70%+27.10%+37.21%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.24%+9.75%+23.11%+20.37%+57.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.30
Hold$389.71-15.51% Downside
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$252.341.37% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.79
Moderate Buy$169.741.36% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.86
Moderate Buy$1,404.14-0.32% Downside

Current Analyst Ratings Breakdown

Latest LLY, AMGN, BIIB, and GILD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$280.00 ➝ $300.00
11/2/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$175.00
11/2/2026
Biogen Inc. stock logo
BIIB
Biogen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$251.00 ➝ $270.00
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy (B+) ➝ Buy (B)
10/30/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$175.00 ➝ $195.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Argus logo
Argus
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$1,300.00 ➝ $1,550.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$1,425.00 ➝ $1,625.00
10/30/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$175.00
10/30/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$160.00 ➝ $175.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$1,650.00
(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$36.75B6.79$33.50 per share13.77$16.08 per share28.69
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.72$22.63 per share11.00$128.01 per share1.94
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B7.05$10.29 per share16.27$10.44 per share16.04
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B20.33$25.10 per share56.13$42.81 per share32.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0928.6718.743.4122.95%124.14%13.18%N/A
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.34106.3815.632.823.37%9.38%5.69%N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$3.16N/A16.61N/A-12.47%-1.85%-0.61%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8145.7228.411.7731.90%86.76%22.03%N/A

Latest LLY, AMGN, BIIB, and GILD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.79$6.45+$0.66$7.08$10.07 billion$10.37 billion
10/29/2026Q3 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.19$2.55+$0.36$1.94$7.81 billion$8.30 billion
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.19%+8.27%62.65%14 Years
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.281.96%+3.04%N/A 10 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.49%+15.18%22.46%11 Years

Latest LLY, AMGN, BIIB, and GILD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.821.98%12/15/202612/15/202612/30/2026
10/27/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.25%11/20/202611/20/202612/11/2026
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.54%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.84
1.38
0.95
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable

Recent News About These Companies

Eli Lilly and Company (NYSE:LLY) EVP Sells 5,000 Shares of Company Stock
 |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-lly-insider-buying-and-selling-2026-11-04/
6,790 Shares in Eli Lilly and Company $LLY Purchased by First Nebraska Trust Co
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-6790-shares-in-eli-lilly-and-company-lly-purchased-by-first-nebraska-trust-co-2026-11-04/
Eli Lilly and Company $LLY Stake Boosted by Factory Mutual Insurance Co.
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-stake-boosted-by-factory-mutual-insurance-co-2026-11-04/
Eli Lilly and Company $LLY Stock Purchased by Gerber Kawasaki Wealth & Investment Management
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eli-lilly-and-company-lly-stock-purchased-by-gerber-kawasaki-wealth-investment-management-2026-11-04/
2,460 Eli Lilly and Company $LLY Shares Sold by BOCHK Asset Management Ltd
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-2460-eli-lilly-and-company-lly-shares-sold-by-bochk-asset-management-ltd-2026-11-04/
Eli Lilly and Company (NYSE:LLY) Stock Gets Price Target Increase from Cantor Fitzgerald
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31177059
Eli Lilly and Company (NYSE:LLY) EVP Anat Hakim Sells 5,000 Shares of Company Stock
November 3 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-eli-lilly-and-company-nyse-lly-evp-anat-hakim-sells-5000-shares-of-company-stock-2026-11-03/
Eli Lilly: Priced For Acceleration, Reporting Deceleration
November 3 at 3:31 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4961727-eli-lilly-priced-for-acceleration-reporting-deceleration?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Lilly’s R&D whirlwind — what the large pharma has taken in and what it’s dropped
November 3 at 3:09 PM  |  pharmavoice.comP
Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor
November 3 at 3:09 PM  |  tikr.comT
Raised Guidance Altering The Investment Case For Eli Lilly Stock?
November 3 at 3:09 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/raised-guidance-altering-investment-case-180837410.html
Top Pharmaceutical Stocks To Watch Today - November 3rd
November 3 at 1:13 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-top-pharmaceutical-stocks-to-watch-today-november-3rd-2026-11-03/
Promising Healthcare Stocks Worth Watching - November 3rd
November 3 at 1:13 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-promising-healthcare-stocks-worth-watching-november-3rd-2026-11-03/
Lilly Updates Early-Stage LY3867070 Study as Investors Await More Data
November 3 at 11:31 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/lilly-updates-early-stage-ly3867070-study-as-investors-await-more-data?utm_source=marketbeat.com&utm_medium=referral
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
November 3 at 10:01 AM  |  zacks.comhttps://www.zacks.com/stock/news/3021549/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks-3021549
LLY Stock Up Almost 10% After a Robust Q3: Time to Buy, Sell or Hold?
November 3 at 8:16 AM  |  zacks.comhttps://www.zacks.com/stock/news/3021389/lly-stock-up-almost-10-after-a-robust-q3-time-to-buy-sell-or-hold?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-3021389
Eli Lilly Just Delivered Another Monster Quarter. But There’s More to This Story Than Weight-Loss Drugs
November 3 at 8:11 AM  |  247wallst.comhttps://247wallst.com/investing/2026/11/03/eli-lilly-just-delivered-another-monster-quarter-but-theres-more-to-this-story-than-weight-loss-drugs/
Eli Lilly Just Delivered Another Monster Quarter. But There's More to This Story Than Weight-Loss Drugs
November 3 at 8:03 AM  |  247wallst.comhttps://247wallst.com/investing/2026/11/03/eli-lilly-just-delivered-another-monster-quarter-but-theres-more-to-this-story-than-weight-loss-drugs/?utm_source=snapi
ETFs Bought $147.9 Million of Eli Lilly (LLY) on Oct. 30
November 3 at 6:58 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/etfs-bought-147-9-million-110111779.html
Eli Lilly Just Gained 22% in a Month: Take Profits, or Buy More?
November 3 at 6:58 AM  |  tikr.comT
One Way Holdings LLC Acquires 1,301 Shares of Eli Lilly and Company $LLY
November 3 at 5:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-one-way-holdings-llc-acquires-1301-shares-of-eli-lilly-and-company-lly-2026-11-03/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo overlaid on a circuit board with a rising stock price line chart in the background.
NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
By Thomas Hughes | October 5, 2026
A Boeing commercial aircraft parked on a tarmac at sunset, with the Boeing logo overlaid on the sky.
Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
By Dan Schmidt | October 28, 2026
Microsoft logo displayed over an illuminated glass office building at dusk, reflected in a water feature.
Microsoft Is Almost Back to $555—Now the Hard Part Begins
By Chris Markoch | October 9, 2026
Power plant with illuminated smokestacks and electrical substation beside transmission towers at sunset.
Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
By Ryan Hasson | October 11, 2026
Comfort Systems USA logo over rooftop HVAC units and piping at a data center facility during sunset.
Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
By Dan Schmidt | October 26, 2026
Amgen stock logo

Amgen NASDAQ:AMGN

$461.26 -4.19 (-0.90%)
Closing price 11/3/2026 04:00 PM Eastern
Extended Trading
$462.84 +1.58 (+0.34%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen stock logo

Biogen NASDAQ:BIIB

$248.93 -0.08 (-0.03%)
Closing price 11/3/2026 04:00 PM Eastern
Extended Trading
$249.53 +0.60 (+0.24%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$167.47 -2.86 (-1.68%)
Closing price 11/3/2026 04:00 PM Eastern
Extended Trading
$169.08 +1.61 (+0.96%)
As of 04:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,408.68 -2.31 (-0.16%)
Closing price 11/3/2026 03:59 PM Eastern
Extended Trading
$1,422.20 +13.52 (+0.96%)
As of 04:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas